DU
Therapeutic Areas
Ocugen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCU400 | Retinitis Pigmentosa | Phase 3 |
| OCU410ST | Stargardt Disease | Phase 2/3 |
| OCU410 | Geographic Atrophy secondary to Dry Age-Related Macular Degeneration | Phase 2 |
| OCU200 | Diabetic Macular Edema, Diabetic Retinopathy, Wet Age-Related Macular Degeneration | Phase 1 |
| OCU500 | Prevention of COVID-19 | IND Cleared |
| OCU510 | Prevention of Influenza | IND Planned |
| OCU520 | Prevention of Flu and COVID-19 | IND Planned |
Leadership Team at Ocugen
DS
Dr. Shankar Musunuri
Chairman, CEO and Co-founder
DA
Dr. Arun Upadhyay
Chief Scientific Officer, Head of Research & Development and Medical
AG
Abhi Gupta
Executive Vice President, Commercial and Business Development
RJ
Rita Johnson-Greene
Chief Financial Officer
KC
Kristen Craft
Head of People and Culture